Stoke Therapeutics announces $75M common stock offering

Stoke Therapeutics announced a proposed underwritten public offering in which it intends to offer and sell, subject to market and other conditions, up to $75M of shares of its common stock. Stoke intends to use the net proceeds from the proposed offering, together with its existing cash and cash equivalents, to fund research, clinical and process development and manufacturing of its product candidates, including late-stage development of STK-001 and further development of STK-002, developing additional product candidates, working capital, capital expenditures, and for other general corporate purposes. J.P. Morgan Securities is acting as sole book-running manager for the offering.